Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

Launched by PETHEMA FOUNDATION · Aug 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called cilta-cel for patients with high-risk smoldering multiple myeloma, a type of blood cancer that can progress to more serious forms. The trial aims to see how effective and safe this treatment is by checking if patients have no detectable cancer cells after receiving cilta-cel, and it will monitor patients for up to five years to assess their progress.

To be eligible for this trial, participants must be at least 18 years old and have specific high-risk features in their smoldering multiple myeloma. They will undergo several health checks to ensure they can participate safely. If enrolled, patients will receive the cilta-cel treatment and will be closely monitored for any side effects and overall health. It's important for potential participants to understand the commitment involved, including regular check-ups and following specific guidelines related to fertility and contraception during and after the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Be ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of informed consent.
• - High-risk SMM defined as having 1 of the following 2 criteria: i) High-risk per "Mayo 20-2-20" criteria defined as presence of any ≥2 of the following:
• • 1. Serum M-protein ≥2 gm/dL
• • 2. Involved to uninvolved FLC ratio ≥20
• • 3. BMPC % ≥20% to \<40% OR ii) Presence of ≥95% of BMPC with an aberrant phenotype within the BMPC compartment and immunoparesis present defined as a reduction of at least 25% below the lower normal limit for ≥1 uninvolved immunoglobulin isotype (only IgG, IgA and IgM will be considered).
• • - Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1.
• • - Have an estimated glomerular filtration rate (eGFR), based on the Modified Diet in Renal Disease (MDRD) 4-variable formula or 24-hour urine collection of ≥40 mL/min during the screening period.
• • - Laboratory values obtained \<21 days prior to Screening: i) Total bilirubin ≤2.0 mg/dL ii) Aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) iii) Alanine transaminase (ALT) ≤3 x ULN
• • - Hemoglobin ≥8.0 g/dL (≥5 mmol/L) (without prior red blood cell \[RBC\] transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted). For subjects who meet the inclusion criteria at screening, transfusion of RBCs is permitted after screening as needed to maintain a hemoglobin level ≥8.0 g/dL.
• • - Neutrophils ≥1.0 × 109/L (prior growth factor support is permitted but must be without support in the 7 days prior to the laboratory test)
• • - Platelets ≥75 × 109/L (must be without transfusion support in the 7 days prior to the laboratory test)
• • - Lymphocyte count ≥0.3\*109/L
• • - Participants should be seronegative for human immunodeficiency virus (HIV) or have controlled disease if seropositive.
• • - A female participant of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study.
• • - A female participant must be either of the following: i) Not of childbearing potential ii) Of childbearing potential and practicing at least 1 highly effective method of contraception throughout the study and through 6 months after the last dose of study treatment. If a female participant becomes of childbearing potential after the start of the study, the female participant must comply with ii).
• • - A female participant using oral contraceptives should use an additional barrier contraceptive method.
• • - A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the cilta-cel infusion. Female participants should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility.
• • A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 1 year after receiving the cilta-cel infusion. If the male participant's partner is a female of childbearing potential, the male participant must use condoms (with or without spermicide) and the female partner of the male participant must also be practicing a highly effective method of contraception. A male participant who is vasectomized must still use a condom (with or without spermicide), but the partner is not required to use contraception.
• • A male participant must agree not to donate sperm for the purposes of reproduction during the study and for 1 year after receiving the last dose of study treatment. Male participants should consider preservation of sperm prior to study treatment as anti-cancer treatments may impair fertility.
• • A male participant must agree not to plan to father a child while enrolled in this study or within 1 year after the last dose of study treatment.
• • Must sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
• • An additional ICF will be collected to get participants authorization to collect the necessary samples for performing the Biological studies indicated in this protocol.
• • Be willing and able to adhere to the lifestyle restrictions specified in this protocol.
• Exclusion Criteria:
• • - History of uncontrolled illness, including but not limited to MGUS, standard risk smoldering myeloma, active myeloma by current IMWG definition, light chain amyloidosis with organ involvement or patients with extramedullary disease.
• • - Non-muscle-invasive bladder cancer treated within the last 24 months that is considered completely cured.
• • - Skin cancer (nonmelanoma or melanoma) treated within the last 24 months that is considered completely cured.
• • Noninvasive cervical cancer treated within the last 24 months that is considered completely cured.
• * Localized prostate cancer (N0M0):
• • i) with a Gleason score ≤6, treated within the last 24 months or untreated and under surveillance.
• • ii) with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
• • iii) history of localized prostate cancer and receiving androgen deprivation therapy and considered to have a very low risk of recurrence).
• • - Adequately treated lobular carcinoma in situ or ductal carcinoma in situ.
• • - History of localized breast cancer and receiving antihormonal agents and considered to have a very low risk of recurrence.
• • - Known allergies, hypersensitivity, or intolerance to cilta-cel or its excipients.
• • - Participant had major surgery or had significant traumatic injury ≤14 days prior to Cycle1Day1.
• * If any of the following exist at screening, participant will be excluded because this trial involves an investigational agent whose genotoxic, mutagenic, and teratogenic effect on the developing fetus and newborn are unknown:
• • i) Pregnant women ii) Nursing women iii) Men or women of childbearing potential who are unwilling to employ adequate contraception
• • Other comorbidity which would interfere with subject's ability to participate in trial, eg, uncontrolled infection, uncompensated heart, or lung disease.
• • Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
• • History of neurodegenerative disease (eg, Parkinson or stroke within 6 months).
• • Medical history of treatment for another malignancy \<2 years before trial enrollment, other concurrent chemotherapy, or any ancillary therapy considered investigational. Note: Bisphosphonates are considered supportive care rather than therapy and are thus allowed while on protocol treatment.
• • Known seropositive for or active viral infection with HIV, HBV, hepatitis C virus (HCV), or SARS-CoV-2 (Coronavirus Disease 2019 \[COVID-19\]).
• • i) Participants who are positive for SARS-COV-2 antibody, HIV1 and 2 antibody, hepatitis B core antibody (HBc), or hepatitis B surface antigen (HBsAg) must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
• • ii) Participants who are positive for HIV1 or 2 infections, with undetectable viral load and on stable antiretrovirals, will not be excluded.
• • iii) Participants with past HCV infection need at least 12 months of sustained virologic response and be negative for RNA to enter.
• • iv) Patients with a high-risk of HBV reactivation (eg, negative for HBV antigen but positive for chronic HBV, with or without anti-serum HBV) must be monitored with DNA and ALT/AST).
• • - Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
• • NOTE: Investigators must ensure that all study enrollment criteria have been met at screening. If a participant's clinical status changes (including any available laboratory results or receipt of additional medical records) after screening but before the first dose of study intervention is given such that the participant no longer meets all eligibility criteria, then the participant must be excluded from participation in the study.